Prime Medicine disclosed its full‑year 2025 financial results, reporting a cash, cash equivalents, investments and restricted cash balance of $191.4 million as of December 31 2025. The company posted a net loss of $201.1 million, a slight increase from the $195.9 million loss recorded in 2024, and generated $4.6 million in collaboration revenue, the majority of which came from a single partnership. The company’s operating expenses rose to $160.6 million, reflecting continued investment in research and development.
Management stated that the $191.4 million cash balance should fund operating expenses and capital expenditures through 2027, assuming the timing of Phase 1/2 trials proceeds as planned. The company reiterated its guidance that the cash runway will support the launch of its Wilson Disease and Alpha‑1 Antitrypsin Deficiency (AATD) liver programs, with IND filings scheduled for the first half of 2026 and initial clinical data expected in 2027.
Prime Medicine also highlighted progress on its PM359 program for chronic granulomatous disease (CGD). The company is in ongoing FDA engagement and intends to file a Biologics License Application after final data alignment. In December 2025, the company published Phase 1/2 data in the New England Journal of Medicine, a milestone that could accelerate regulatory approval. The company’s cystic fibrosis initiative, supported by a $24 million investment from the Cystic Fibrosis Foundation, continues to advance preclinical studies.
The market reacted to the earnings announcement with a roughly 7 % decline in the company’s stock on March 3 2026, reflecting investor caution amid the company’s continued net losses and modest revenue. Analyst sentiment was mixed: Lifesci Capital upgraded Prime Medicine to “strong‑buy,” while Weiss Ratings maintained a “sell (d‑)” rating and Wall Street Zen downgraded the stock to “sell” in November 2025.
In a statement, CEO Allan Reine said, “We are shaping the future of genetic medicine by advancing a platform that is rapidly emerging as the predominant gene editing technology. With Prime Editing, we have the opportunity to permanently and safely correct disease‑causing mutations across a broad range of indications, supported by our comprehensive IP estate.” He added, “With this foundation, our vision is bold and unwavering: to strategically deliver on the promise of Prime Editing and ensure patients have access to transformative therapies capable of delivering durable, and potentially lasting cures.”
Prime Medicine’s earnings release underscores the company’s continued focus on pipeline development and cash management, while highlighting the progress of its liver franchise and the potential for accelerated approval of its PM359 CGD product. The company’s ability to secure future funding and achieve regulatory milestones will be critical for its long-term prospects.
revised_sentiment_rating":0} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.